Pfizer and Astellas have, this morning, announced that the addition of enzalutamide to standard androgen deprivation (ADT) has led to improved outcomes in men with metastatic, hormone-sensitive prostate cancer (mHSPC). … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: ADT, androgen, ARCHES, deprivation, enzalutamide, hormone, outcome, sensitive, standard, trial | 2 Comments »
We finally have some published data — albeit not a lot — on the use of one of the PD-1 inhibitors (pembrolizumab, also known as Keytruda) in the treatment of late-stage prostate cancer. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: activity, efficacy, Keytruda, outcome, pembrolizumab, safety, trial | 5 Comments »
A report on the UroToday web site has addressed a presentation given this week at the ESMO 2018 Congress in Munich, Germany, that is relevant to the potential value of taking a statin while you are being treated for very late stage prostate cancer. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: cabazitaxel, data, interpretation, outcome, statin | 1 Comment »
The following was brought to our attention by Arthur as a consequence of a question posed on Ask Arthur by a reader within the past 24 hours. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: alpha-blocker, localized, outcome, prazosin, radiation, tamulosin | 3 Comments »
Back in January this year we commented on a technique known as Retzius-sparing radical prostatectomy, which — according to its advocates — is said to facilitate recovery of erectile function post-surgery. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: biochemical, outcome, recurrence, Retzius-sparing, risk, surgery | Leave a comment »
A clinical research team from the Mayo Clinic (Routman et al.) has reported 10-year oncological results on 974 consecutive low- and intermediate-risk patients treated with low-dose-rate brachytherapy monotherapy (using iodine-125 seeds) from 1998 to 2013. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: brachytherapy, intermediate, low, low-dose-rate, monotherapy, outcome, risk, seeds | 3 Comments »
